To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
DOX-Inducible iPSC-Derived Dopamine Neuron
Human iPS Cell
Inducible iPSC line in which addition of doxicycline to the media stimulates differentiation into dopamine neurons with 90% purity in a matter of days.
Estimated Availability: Mid 2026
Total Rab 29 Antibody (Hu)
Antibody
Rabbit monoclonal antibody directed against the human total Rab 29 protein. Suitable for immunoblot and immunoprecipitation experiments. This antibody epitope was mapped to amino acids 141-150.
Miro1 Antibody (WB)
Antibody
Rabbit monoclonal antibody directed against human/mouse/rat Miro1, validated for use as a detector antibody in immunoblotting applications.
LRRK2 N2081D KI Mouse*
Mouse Model
Mice expressing the conserved LRRK2 N2081D variant introduced to exon 41 of the mouse Lrrk2 gene using CRISPR/Cas9 at endogenous levels. Model was donated by Dr. Zhenyu Yue at Mount Sinai School of Medicine, and made available through the MJFF Sponsored Tools Program. RRID:IMSR_JAX:037193
LysoFix-GBA FQ10 (Lysosomal GCase Probe Yellow)*
Assay
This GCase activity probe is a cell-permeable reporter for GCase activity, fluoresces upon glucocerebrosidase activation, facilitating the detection and monitoring of GBA1 activity. These probes were generated and kindly shared through the MJFF Sponsored Tools Program by David Vocadlo.
CLN3 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in CLN3, including heterozygous and homozygous R334H, heterozygous and homozygous V330I, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026
CTSB Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in CTSB for heterozygous and homozygous knockout. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP).Estimated Availability: Q1 2026
GALC Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in GALC, including heterozygous and homozygous R101X, heterozygous and homozygous Y541S, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026.
GPNMB Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in GPNMB, including knockout heterozygous and homozygous, heterozygous, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026.
ITSN1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in ITSN1, including heterozygous and homozygous R992* and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026.
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic